Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

SAB Biotherapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.96) Estimate

Author: Benzinga Newsdesk | May 20, 2024 05:49pm

SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.96) by 55.21 percent. This is a 186.67 percent decrease over losses of $(0.15) per share from the same period last year.

SAB reaffirms it has sufficient cash, assuming the receipt of funds upon the exercise of all outstanding Tranche B warrants, that is expected to be sufficient to fund its operations into 2026.

Posted In: SABS